Immuron expands into U.S. market with PROIBS®

MELBOURNE, Australia, Sept. 04, 2026 /CourierPR/ -- Immuron Limited, the Australian biopharmaceutical company, has announced a significant expansion into the U.S. market with the launch of PROIBS®. The company has entered into an exclusive distribution agreement with Calmino group AB, a Swedish life science firm, to bring PROIBS® to the United States.

PROIBS®, a medical device derived from Aloe barbadensis Mill., is designed to address abdominal pain, bloating, and digestive issues such as diarrhea and constipation. The product, which has been available in the Swedish market for over a decade, has garnered positive feedback from users, with 94% finding it helpful and 98% willing to recommend it to others.

According to Flavio Palumbo, Immuron's Chief Commercial Officer, the company is leveraging its success with Travelan® to drive growth in the U.S. market. "PROIBS® is a strategic addition to our portfolio, offering our customers a proven, premium product that improves daily life," Palumbo stated. "We are excited to provide a science-backed solution that has been well-received in Europe."

Tobias Kisker, CEO and founder of Calmino group AB, expressed enthusiasm about the collaboration. "Our partnership with Immuron is expanding beyond Australia, as we now target the United States market," Kisker said. "We are confident in the product's efficacy and are looking forward to reaching a broader audience."

The U.S. digestive health supplement market is valued at $4.16 billion, according to Mordor Intelligence, making it a prime target for Immuron. The company aims to capitalize on this market by offering a medical device with a proven track record and a strong safety profile.

In a usability study involving 1,003 users, 91% of those who used PROIBS® reported an improvement in their daily lives. "The positive user feedback and the strong safety profile of PROIBS® make it an attractive option for individuals seeking relief from digestive discomfort," Palumbo noted.

Immuron's focus on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases is complemented by the introduction of PROIBS®. The company's growth strategy includes expanding its portfolio of innovative digestive health products, with PROIBS® serving as a key component.

With its entry into the U.S. market, Immuron aims to tap into the significant digestive health market and provide a science-driven solution to those in need. "We are committed to offering innovative and effective products that improve the quality of life for our customers," Palumbo concluded.

The collaboration between Immuron and Calmino group AB marks a strategic move to enhance the company's presence in the global market. As Immuron continues to develop and commercialize its products, the launch of PROIBS® in the United States is a significant step toward achieving its growth objectives.